Reviewer's report

**Title:** SNP55, a new functional polymorphism of MDM2-P2 promoter affected by NFkB p50 in endometrial cancers

**Version:** 2  **Date:** 22 January 2015

**Reviewer:** Tomas Kirchhoff

**Reviewer's report:**

**Major Compulsory Revisions**

Several specific clarifications may be helpful for the readers:

1) no sufficient description on how the SNP55 was identified?

What is the relationship with SNP309? Are the two in LD? Was SNP55 identified previously in 1000G?

If there is any relationship - some idea of haplotype structure involving both would be helpful. However commenting on this would perhaps be sufficient given the scope of the study. But regardless, the readers may want to know more about the SNP information.

On the related note - it would helpful to include rs# for both SNPs respectively as it is difficult to decipher from the text (sometime they mention SNP55, sometimes rs#, but there is no clear connection anywhere both can be seen together - e.g. SNP55 (rs.....).)

2) while authors state the SNP55 is associated with ASE in the endometrial tissues, is there any evidence for eQTL of this variant in other tissues analyzed previously in twin studies (e.g. MOTHER consortia, which is publically available)? This would be helpful as it would provide further support for the general functional role of this SNP. If not, some brief explanation on why SNP55 associates with ASE in endometrial tissues but not in other tissues should be provided. For instance, likely due to the presence of other genomic factors? This should be discussed.

**Minor Essential Revisions:**

1. There are many grammatical problems and the manuscript should be edited accordingly.

2. The study is convoluted at places and the findings are delivered in less logical way sometimes. This likely relates to language problem and it requires extensive editing.

**Level of interest:** An article whose findings are important to those with closely related research interests
Quality of written English: Needs some language corrections before being published

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

I declare that I have no competing interests